Related Experiment Videos
[Autoimmune bullous skin diseases]
1Clinique dermatologique, hôpital Charles-Nicolle, Rouen, France.
La Revue De Medecine Interne
|April 30, 1999
Summary
Recent advances in autoimmune bullous skin diseases reveal new types and target antigens. Research focuses on novel treatments beyond corticosteroids, including immunoadsorption, to improve patient outcomes and reduce mortality.
Area of Science:
- Dermatology
- Immunology
- Pathogenesis of skin diseases
Context:
- Autoimmune bullous skin diseases (ABSDs) represent a group of conditions with significant morbidity and mortality.
- Recent advancements have elucidated the complex pathogenesis of various ABSDs, identifying specific autoantigens.
- Paraneoplastic pemphigus (PNP) is a distinct entity with unique clinical and immunological features.
Purpose:
- To review recent advances in the pathogenesis of autoimmune bullous skin diseases.
- To describe newly identified types of ABSDs.
- To summarize current and emerging treatment strategies for ABSDs.
Summary:
- Autoimmune bullous skin diseases are caused by autoantibodies targeting specific adhesion molecules (desmoglein 1 and 3 in pemphigus vulgaris/foliaceus), desmosomal plaque proteins (plakins in PNP), or hemidesmosomal proteins (BPAG1 and BPAG2 in bullous pemphigoid).
- Mortality rates for ABSDs range from 10-40%, primarily due to infections and cardiovascular complications.
- Adjuvant therapies alongside corticosteroids are under investigation, with topical corticosteroids showing promise for bullous pemphigoid and some pemphigus cases.
Impact:
- Improved understanding of ABSD pathogenesis facilitates targeted therapies.
- Development of novel treatments like immunoadsorption offers potential alternatives to corticosteroids.
- Future research directions include validating new therapeutic approaches to improve patient survival and quality of life.